Nov 03, 2022 / 12:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Abeona conference call Phase III clinical trial. (Operator Instructions) It is now my pleasure to turn the floor over to your host, Mr. Greg Gin, VP of Investor Relations and Corporate Communications. Greg, over to you.
Gregory Gin - Abeona Therapeutics Inc. - VP of IR & Corporate Communications
Thank you, Jenny. Good morning, everyone. I would like to welcome and thank everyone for joining us for our conference call to review the positive top line results from our pivotal Phase III VIITAL study of EB-101 in patients with recessive dystrophic epidermolysis bullosa, or RDEB. The press release announcing the top line results is available on our website at www.abeonatherapeutics.com.
Before we begin, I will remind everyone that the presentation may contain projections and forward-looking statements regarding future events. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities
Abeona Therapeutics Inc To Discuss the Positive Topline Results Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot